Vaccine composition

Abstract

There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.

1 . A method of treating cancer in a mammal said cancer being a tumour expressing an HPV protein, said method comprising:
 a) administering a first virus comprising a nucleic acid capable of expressing a protein comprising an HPV tumour associated antigen, wherein said first virus is capable of generating immunity to said HPV tumour associated antigen;   b) administering a second virus, said second virus being a Vesiculovirus, said second virus comprising a nucleic acid capable of expressing a HPV tumour associated antigen, wherein said second virus is capable of providing a therapeutic oncolytic effect in said mammal;   wherein said first virus is immunologically distinct and physically; and   wherein either (i) the HPV tumour associated antigen comprises an amino acid sequence that is at least 80% identical to SEQ ID NO. 7; or (ii) the second virus is Maraba MG1.   
     
     
         2 . The method of  claim 1 , wherein said second virus is Maraba MG1. 
     
     
         3 . The method of  claim 2 , wherein the HPV tumour associated antigen expressed by said nucleic acid in at least the first or second virus comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 7. 
     
     
         4 . The method of  claim 3 , wherein the amino acid sequence is at least 90% identical to SEQ ID NO: 7. 
     
     
         5 . The method of  claim 4 , wherein the amino acid sequence comprises SEQ ID NO: 7. 
     
     
         6 . The method of  claim 4 , wherein the amino acid sequence consists of SEQ ID NO: 7. 
     
     
         7 . The method of  claim 5 , wherein the amino acid sequence is encoded by the nucleotide sequence of SEQ ID NO: 8. 
     
     
         8 . The method according to  claim 5 , wherein the Maraba MG1 genome comprises a reverse complement and RNA version of a nucleotide sequence of SEQ ID NO: 9. 
     
     
         9 . The method of  claim 1 , wherein the HPV tumour associated antigen expressed by said nucleic acid in at least the first or second virus that comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 7. 
     
     
         10 . The method of  claim 8 , wherein the amino acid sequence is at least 90% identical to SEQ ID NO: 7. 
     
     
         11 . The method of  claim 9 , wherein the amino acid sequence comprises SEQ ID NO: 7. 
     
     
         12 . The method of  claim 10 , wherein the amino acid sequence consists of SEQ ID NO: 7. 
     
     
         13 . The method of  claim 11 , wherein the amino acid sequence is encoded by the nucleotide sequence of SEQ ID NO: 8. 
     
     
         14 . The method according to  claim 1 , wherein said first virus is administered intramuscularly and said second virus is administered intravenously. 
     
     
         15 . The method according to  claim 1 , wherein said first and second virus both express the same HPV tumour associated antigen. 
     
     
         16 . The method of  claim 14 , wherein the HPV tumour associated antigen comprises SEQ ID NO: 7. 
     
     
         17 . The method of  claim 1 , wherein the cancer expresses HPV E6 or E7 proteins as antigenic proteins. 
     
     
         18 . The method of  claim 1 , wherein the cancer is cervical cancer.